Glancy Prongay Wolke & Rotter LLP Announces Investigation of Integer Holdings Corporation (ITGR) on Behalf of Investors
MWN-AI** Summary
Glancy Prongay Wolke & Rotter LLP, a prominent law firm focused on shareholder rights, has initiated an investigation into Integer Holdings Corporation (NYSE: ITGR) on behalf of its investors. The investigation stems from concerns that Integer's board of directors may have breached its fiduciary duties to shareholders.
The catalyst for this investigation was Integer's recent announcement on October 23, 2025, where the company significantly lowered its full-year sales guidance to between $1.840 billion and $1.854 billion, falling short of prior expectations. During an earnings call, management disclosed that sales for three new products, including two electrophysiology devices, are expected to decline in 2026 due to slower than anticipated market adoption. Furthermore, sales growth in the Cardio & Vascular segment is projected to decelerate, particularly due to declining demand for these electrophysiology products.
This disappointing news resulted in a substantial sell-off of Integer's shares, with the stock plummeting by $35.22, or 32.3%, to close at $73.89 on the same day. This steep decline has raised serious questions regarding the management's disclosures and decision-making processes leading up to this announcement.
For shareholders who acquired Integer shares before July 2024, Glancy is inviting participation in the investigation and encouraging them to reach out for more information regarding their rights and options. The firm is open to speaking with investors to discuss potential claims.
Glancy Prongay Wolke & Rotter LLP is well-regarded in securities litigation, with a track record of securing substantial recoveries for investors across various sectors. Shareholders seeking guidance can contact the firm via email or phone.
MWN-AI** Analysis
The recent announcement by Glancy Prongay Wolke & Rotter LLP regarding their investigation into Integer Holdings Corporation (ITGR) raises several important points for current and prospective investors. On October 23, 2025, Integer Holdings lowered its sales guidance for the year, projecting a range of $1.840 billion to $1.854 billion, which fell short of prior expectations. Furthermore, the Company's forecast for organic sales growth suggests stagnation, with projections indicating declines in key growth areas, particularly in electrophysiology products.
The immediate reaction from the market was significant, with ITGR's stock plummeting by over 32% to $73.89 per share. This sharp decline indicates that investor confidence has been severely shaken, leading to the investigation into whether the board's actions constituted a breach of fiduciary duty. Investors should assess the implications of this news carefully.
For those who currently hold shares purchased before July 2024, participating in the investigation may provide an opportunity to reclaim potential losses, should evidence of board negligence arise. However, prospective investors should exercise caution. The forecasted deceleration in sales growth, coupled with the disappointing performance of newly launched products, suggests that Integer may face a challenging operational landscape moving forward.
From a broader market perspective, oscillations in investor sentiment about corporate governance may influence ITGR's valuation in the short term. If the investigation surfaces substantive claims against the board, a further downturn could follow. Conversely, should the company manage to stabilize and implement corrective strategies, recovery may be possible. Thus, maintaining a vigilant approach to market developments and corporate communications is imperative for both current shareholders and potential investors considering an entry into this stock.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Glancy Prongay Wolke & Rotter LLP , a leading national shareholder rights law firm, today announced that it is investigating potential claims against the board of directors of Integer Holdings Corporation (“Integer” or the “Company”) (NYSE: ITGR ) concerning whether the board breached its fiduciary duties to shareholders.
IF YOU ARE AN INTEGER HOLDINGS CORPORATION (ITGR) SHAREHOLDER, CLICK HERE TO PARTICIPATE.
What Happened?
On October 23, 2025, before the market opened, Integer reduced its full-year 2025 sales guidance to a range of $1.840 billion to $1.854 billion, below prior expectations, and informed investors that it anticipated net sales growth of –2% to 2% and organic sales growth of 0% to 4% for 2026. During the accompanying earnings call, management revealed that sales of three new products were expected to decline in 2026—including two electrophysiology devices—and that market adoption of these products had been slower than forecasted. The Company further stated that Cardio & Vascular sales growth was expected to decelerate due to declines in those electrophysiology products, with the impact continuing into 2026.
On this news, Integer’s stock price fell $35.22 per share, or 32.3%, to close at $73.89 per share on October 23, 2025, thereby injuring investors.
Contact Us To Participate or Learn More:
If you still hold Integer shares purchased before July 2024 and wish to discuss this matter with us, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: shareholders@glancylaw.com
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com .
Follow us for updates on LinkedIn , Twitter , or Facebook .
Whistleblower Notice
Persons with non-public information regarding Cogent should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@glancylaw.com .
About Glancy Prongay Wolke & Rotter LLP
Glancy Prongay Wolke & Rotter LLP (“GPWR”) is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPWR has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPWR was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements.
With four offices across the country, GPWR’s nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPWR’s lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR’s past successes have been widely covered by leading news and industry publications such as The Wall Street Journal , The Financial Times , Bloomberg Businessweek , Reuters , the Associated Press , Barron’s , Investor’s Business Daily , Forbes , and Money .
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260303489040/en/
Contact Us:
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email: shareholders@glancylaw.com
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com .
FAQ**
What specific actions did the board of directors of Integer Holdings Corporation (ITGR) take that may constitute a breach of fiduciary duties to shareholders, particularly following the recent sales guidance reduction?
How does the reduction in Integer Holdings Corporation (ITGR) sales guidance impact the company's long-term financial outlook and growth potential in the medical device market?
What legal recourse do shareholders of Integer Holdings Corporation (ITGR) have in light of the recent stock price decline and the potential breach of fiduciary duties by the board?
What are the potential implications for future product development and market strategy at Integer Holdings Corporation (ITGR) following the disappointing sales forecasts for new electrophysiology devices?
**MWN-AI FAQ is based on asking OpenAI questions about Integer Holdings Corporation (NYSE: ITGR).
NASDAQ: ITGR
ITGR Trading
3.05% G/L:
$87.085 Last:
341,269 Volume:
$83.48 Open:
